Bio-Research.AI (formerly Efortless Update)’s Post

#GPRC5D Distinctly expressed in multiple myeloma cells, GPRC5D, an orphan receptor, emerges as a promising treatment target alongside #BCMA. Recent findings from the 65th ASH annual meeting in late 2023 highlight clinical trials focusing on GPRC5D-targeted therapies, including dual-targeted and CAR-T cell treatments. In our latest article, we discussed the target structure, drug development, and how we can help. Read more: https://lnkd.in/ev2-d_EW

We are very excited to expand our pipeline with the potential of best-in-class therapeutics for patients being underserved by existing treatment options in multiple inflammatory diseases. We have now secured the exclusive rights to develop and commercialize a Phase 2-ready IL-18 targeted fusion protein from #AprilBio. This long-acting injectable fusion protein is designed to neutralize the signal pathway of IL-18 for the regulation of inflammation. The Phase 1 trial demonstrated good safety and tolerability, favorable pharmacokinetics, and target engagement and we are ready to initiate on a Phase 2 clinical trial in first half of 2025. https://lnkd.in/gKgQV2H6

Humanized animal models are critical tools to facilitate efficacy evaluation of novel anti-human antibody therapeutics. Many of Biocytogen’s humanized mouse models have been engineered to specifically express human forms of immune-checkpoints and/or cytokine signaling molecules on an immunocompetent background. These models offer a robust and cost-effective way to evaluate in vivo therapeutic efficacy of biologics. If you’re attending AACR, check out our 11 posters featuring our off-the-shelf mouse/rat models, or set up a meeting at booth 939:  https://lnkd.in/dTTkD7z3 #AACR2024 #AACRConference #AACRMeeting #CancerAwareness #TumorResearch #immunodeficient #preclinicalresearch #immunotherapy #cancerresearch #cancertherapy #PreclinicalStudies #HumanizedModels #renbiologics #antibodylibrary

Small Molecule Drugs Remain Vital in Addressing Refractory Multiple Myeloma: Small molecule agents continue to be beneficial additions to multiple myeloma treatment, even with the development of T-cell redirected therapies. #finance #pharmacy #lifesciences

Have you ever wondered about the long-term effects of medical treatments we undergo? Recently, there's been a lot of buzz around the potential for micro clots forming over time from certain experimental injections. This raises a crucial question: should we be more proactive in discussing these possibilities with our doctors? Micro clots, though tiny, can have significant impacts on our health. They might not be immediately noticeable, but over time, they could lead to more serious conditions. It's essential to stay informed and vigilant about what we put into our bodies. When was the last time you had an in-depth conversation with your healthcare provider about the potential long-term effects of treatments? Are we asking the right questions, or are we taking things at face value? Healthcare is a partnership between you and your doctor. It's not just about following orders; it's about understanding the implications and making informed decisions together. So, what say you? Have you discussed the possibility of micro clots with your doctor? Do you think this is something we should be more concerned about, or is it just another medical myth? Let's start a conversation. Share your thoughts and experiences in the comments below. Your insights could help others make more informed decisions about their health. #HealthAwareness #MedicalQuestions #InformedDecisions -

On Dec 4th from 1 pm to 3 pm US East Coast time, given the increasing interest in oligonucleotides and in antibody-drug conjugates, subject matter experts from the FDA are holding a webinar that will discuss the unique considerations for oligonucleotide therapeutics and antibody-drug conjugates concerning topics such as dose selection, exposure-response analysis, organ impairment, drug interactions, QTc assessment, and immunogenicity. To support the growing number of novel therapeutics, the final guidances on oligonucleotide therapeutics and antibody-drug conjugates will be referenced as part of this discussion. This is a free virtual meeting and you can register through: https://lnkd.in/g6WpeWEy

Intellia Therapeutics, Inc. Therapeutics has started their MAGNITUDE Phase 3 trial with the CRISPR-based drug NTLA-2001 for the treatment of TTR amyloidosis (NCT06128629). Intellia had previously published encouraging results of a Phase I study, showing a 87% reduction of serum TTR levels 28 days after a single dose of NTLA-2001. In the MAGNITUDE study, patients will be followed up on CV events, TTR levels and KCCQ-OS score for at least 18 months after a single dose of NTLA-2001. #amyloidosis #crispr

BREAKING - New Arcturus Therapeutics ARCT-154 Replicon Injection (self-amplifying mRNA) trial data released. 5 deaths occurred among the injected in study phase 3b. Injected participants experienced a 90% adverse event rate (74.5% systemic - 15.2% required medical attention) after the first dose in study phases 1, 2, and 3a combined. Many of the authors are full time employees of Arcturus Therapeutics. Thus, the study conclusions are more likely to be biased. ARCT-154 is already approved for adults in Japan... https://lnkd.in/eHwZqdex Nicolas Hulscher, MPH 

We are very happy to announce that pharma& has entered into an agreement with Dayton Therapeutics to acquire the global rights for satraplatin. Satraplatin, an investigational agent, is in development to potentially be the world’s first approved orally administered precision platinum therapy. Recent advances in AI-powered genetic and molecular research modeling have identified potential indications in rare hematologic cancers, including primary central nervous system lymphoma (PCNSL) and T-cell lymphoma, based on sensitivity biomarkers, including the BCL2 gene mutation and MTAP deficiency. pharma& intends to pursue potential indications in rare hematologic cancers such as relapsed or refractory PCNSL. https://lnkd.in/dy6q4en5

Exciting read on siRNA therapeutics from Naim Nazef and the promising future applications, especially when conjugated with #monoclonalantibodies or GalNAc. The potential for #siRNA therapies seems limitless! #therapeutics #Innovation